# Perampanel Titration and Cognitive Effects

> **NCT04417907** · PHASE4 · TERMINATED · sponsor: **Kimford Jay Meador** · enrollment: 29 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Perampanel 1 week titration
- **DRUG:** Perampanel 2 week titration
- **DRUG:** Perampanel 4mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04417907
- **Lead sponsor:** Kimford Jay Meador
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-20
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Study sponsor no longer provided funding.
- **Last updated:** 2024-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04417907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04417907, "Perampanel Titration and Cognitive Effects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04417907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*